Briefs: RPG Life Sciences and Lasa Supergenerics

Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline

Aptar’s nasal unidose system delivers FDA-approved neffy

This marks the first regulatory approval worldwide for nasally-delivered epinephrine

Lupin receives EIR from USFDA for its Dabhasa facility

The facility is a part of Lupin Manufacturing Solutions

Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth

Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas

Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US

The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term

USFDA completes inspection of Lupin's Dabhasa facility with no observations

The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations

Asahi Kasei Bioprocess and Axolabs partner to accelerate oligonucleotide therapeutics development

The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility

Shivalik Rasayan’s API facility gets 7 observations from USFDA

These observations are procedural in nature and will be responded within the stipulated time

Asahi Songwon Colors acquires remaining 22% stake in Atlas Life Sciences

Asahi Songwon Colors' shareholding in ALSPL has increased from 78% to 100%

Asahi Kasei Medical and AW Technologies enter exclusive distribution agreement for TrachFlush in Japan